Evidence map›Paper›PMID 39373623›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025

Alcohol Consumption and Smoking History at the Time of Diagnosis and the Risk of Colorectal Cancer Recurrence and Mortality: Results from the ColoCare Study.

Nicole C Loroña, Caroline Himbert, Jennifer Ose, Stacey A Cohen, Ildiko Strehli, Cornelia M Ulrich, Sofia Cobos, Esther Jean-Baptiste, Amanda M Bloomer, Jane C Figueiredo and 11 more

Abstract readMulticenter Study
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. [Ethanol promotes oxaliplatin resistance in colorectal cancer by activating the TGF‑β/Smad/P21 signaling axis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Nicole C LoroñaDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0002-8302-3157
Caroline HimbertHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-4084-8340
Jennifer OseHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-2030-9676
Stacey A CohenDivision of Hematology/Oncology, University of Washington, Seattle, Washington.ORCID 0000-0002-6207-9856
Ildiko StrehliHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-1127-2186
Cornelia M UlrichHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-7641-059X
Sofia CobosPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-3089-5338
Esther Jean-BaptisteDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-5677-3104
Amanda M BloomerDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-2737-8631
Jane C FigueiredoDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0001-8040-3341
Biljana GigicDepartment of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-8085-2072
Sheetal HardikarHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-0292-6168
Meghana KarchiUniversity of Tennessee Health Science Center, Memphis, Tennessee.ORCID 0009-0004-2857-6789
Matthew MutchDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-5368-3907
Anita R PeoplesHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-3645-3960
Martin SchneiderDepartment of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0001-8215-7359
David ShibataUniversity of Tennessee Health Science Center, Memphis, Tennessee.ORCID 0000-0002-5670-423X
Erin M SiegelDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0003-1779-2510
Adetunji T ToriolaSiteman Cancer Center, St. Louis, Missouri.ORCID 0000-0003-1079-2606
Elizabeth H WoodUniversity of Tennessee Health Science Center, Memphis, Tennessee.ORCID 0009-0003-1068-029X
Christopher I LiPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-1543-0743

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Developing Data-Driven Cancer ResearchersT32CA009168 · NCI · UNIVERSITY OF WASHINGTON · PI STEPHEN M SCHWARTZ, MICHAEL Chiao-An WU · 1985 to 2026
$10.1M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Adipose tissue-colorectal tumor cross-talk: new targets for breaking the obesity-cancer linkR01CA254108 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HURSTING, STEPHEN D, ULRICH, CORNELIA M · 2021 to 2025
$3.2M
Geriatric assessment domains in relation to treatment outcomes among older adults with colorectal cancerR01AG083580 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheetal Hardikar · 2024 to 2026
$2.3M
Diabetes, Medications and the Cost-Effectiveness of Screening for Colorectal NeoplasiaK07CA222060 · NCI · UNIVERSITY OF UTAH · PI HARDIKAR, SHEETAL · 2018 to 2022
$791k
National Cancer Institute (NCI) P30CA076292National Cancer Institute (NCI) R01CA189184National Cancer Institute (NCI) R01CA254108National Cancer Institute (NCI) T32CA00916National Cancer Institute (NCI) U01CA206110NCI NIH HHS K07 CA222060NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA254108NCI NIH HHS T32 CA009168NCI NIH HHS U01 CA206110NIA NIH HHS R01 AG083580
6 · The paper itself

Abstract

backgroundFindings from studies investigating the impacts of alcohol use and smoking on colorectal cancer outcomes are inconclusive. This study aimed to investigate associations between alcohol use and smoking status at the time of diagnosis on recurrence and overall mortality among patients with colorectal cancer.

methodsThe present study included 2,216 stage I-IV patients with colorectal cancer from the longitudinal multicenter ColoCare Study, with available data on recurrence and colorectal cancer-specific mortality. Cox proportional hazards models adjusted for age, sex, race, ethnicity, stage, tumor site, treatment, comorbidities, body mass index, and study site were fit, with imputations for missing data.

resultsWe observed 235 recurrences and 308 colorectal cancer-specific deaths over an average of 3 years of follow-up. After adjusting for confounders, current alcohol consumption and ever smoking, relative to not current consumption and never smoking, respectively, were not statistically significantly associated with colorectal cancer recurrence [alcohol-HR, 0.95. 95% confidence interval (CI), 0.71-1.29; ever smoking-HR, 0.98, 95% CI, 0.75-1.29] or colorectal cancer-specific mortality (alcohol-HR, 0.95. 95% CI, 0.74-1.22; ever smoking-HR, 0.98, 95% CI, 0.77-1.24).

conclusionsNo associations were observed between alcohol and smoking at diagnosis and clinical outcomes in this well-annotated longitudinal cohort. IMPACT: Our cohort study reports no significant associations; however, limiting alcohol use and avoiding smoking are health behaviors recommended for colorectal cancer survivors for prevention of other cancers and chronic conditions.

Indexed as

Alcohol DrinkingColorectal NeoplasmsNeoplasm Recurrence, LocalSmokingAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedRisk Factors

Identifiers

PMID39373623
PMCPMC11717602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.